MAPT and Alzheimer disease: Therefore, this study aimed to evaluate whether the levels of blood miRNAs (1) predict the P-tau/Aβ42 ratio in the CSF, (2) can be used to differentiate patients with AD from cognitively normal controls, and (3) can effectively discriminate AD from VaD, PDD, bvFTD, and DLB.